AstraZeneca
AstraZeneca eyes success in immuno-oncology combinations
May 14, 2015Sales and Marketing ASCO, AZ, AstraZeneca, CTLA-4, MEDI4736
An investigational immuno-oncology drug combination from AstraZeneca has shown promise in its most recent trial, although concerns over its side …
AstraZeneca makes a move into precision medicine
May 13, 2015Research and Development, Sales and Marketing AstraZeneca, Precision Medicine, cardiovascular diseases, diabetes, mhi
AstraZeneca has signalled its intention to ramp up the use of personalised medicine strategies to find new candidate drugs and …
Working Life: AstraZeneca’s Jonathan Day
May 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Jonathan Day, Working Life
How did you find your way into your current role? By way of background, I trained in medicine at the …
AstraZeneca looks to oncology match-ups to boost sales
April 24, 2015Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor
AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
AstraZeneca lung drug shows promise
April 20, 2015Sales and Marketing AZ, AZD9291, AstraZeneca, European Lung Cancer Congress, NSCLC, Orphan
AstraZeneca’s non-small cell lung cancer offering AZD9291 has been shown to delay disease progression by over a year. Data presented …
AstraZeneca bags another FDA orphan status in cancer
April 17, 2015Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib
The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …
AstraZeneca signs immuno-oncology deal with UK firm
April 16, 2015Research and Development, Sales and Marketing AstraZeneca, IMCgp100, MEDI4736, MedImmune, Oxford, immuno-oncology, immunocore, melanoma, tremelimumab
UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies of potential new cancer treatments. …
FDA grants AstraZeneca immune drug orphan status
April 15, 2015Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab
The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …
AZ and Takeda diabetes drugs get FDA safety update
April 15, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, diabetes, saxagliptin
An FDA advisory committee has said that the labels of two type 2 diabetes drugs should be changed to warn …
AstraZeneca partners with PatientsLikeMe
April 14, 2015Sales and Marketing AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease
AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of …
Drug development showcasing at AACR conference
April 13, 2015Research and Development, Sales and Marketing American Association of Cancer Research, AstraZeneca, Bayer, Genentech, Novartis, aacr
This month’s American Association of Cancer Research conference is set to showcase the latest studies in oncology. Roche’s biotech subsidiary …
AstraZeneca diabetes drug could ‘significantly’ increase mortality
April 13, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, saxagliptin
AstraZeneca’s diabetes drug Onglyza may lead to a ‘significant increase’ in risk of death according to a new analysis from …
Pfizer is pharma’s biggest advertiser
March 31, 2015Medical Communications, Sales and Marketing AbbVie, AstraZeneca, Pfizer, advertising, adverts, dtc, lilly
US giant Pfizer spends far more on direct-to-consumer advertising than any other pharma firm according to new data from Kantar …
Addressing the adherence gap
March 30, 2015Research and Development, Sales and Marketing AstraZeneca, Kings College London, Professor John Weinman, adherence
Poor medication use in patients with long-term health conditions is widely recognised as a global problem that urgently needs to …
GSK and UK government agree meningitis B vaccine deal
March 30, 2015Sales and Marketing AstraZeneca, Bexsero, GSK, Novartis, meningitis v, vaccines
The UK government has agreed a deal with GlaxoSmithKline to provide its meningitis B vaccine Bexsero on the NHS, after …
